Firehawk Aerospace
Series C in 2025
Firehawk Aerospace is a private aerospace company focused on advanced rocket propulsion technology. It develops rocket engines and propulsion systems with efficiency and reliability comparable to liquid bi-propellant engines while maintaining safety and simplicity akin to hybrid engines. The firm uses proprietary additive manufacturing to produce 3D-printed fuel grains tailored to specific sizes and thrust profiles, enabling customized, scalable propulsion solutions. Founded in 2018 and based in Melbourne, Florida, with an additional office in Tulsa, Oklahoma, Firehawk aims to improve space transportation efficiency, safety, and cost competitiveness.
Alto Pharmacy
Convertible Note in 2024
Founded in 2015, Alto Pharmacy is America's leading digital pharmacy, transforming the $500 billion pharmaceutical industry. It combines expert pharmacist care with purpose-built technology to deliver a more convenient and affordable medication experience for customers. With over three million prescriptions fulfilled and expansion into twelve markets, Alto offers medication management and scheduled delivery through its mobile app, boasting an industry-leading NPS score of 86.
Raven Space Systems
Pre Seed Round in 2024
Raven Space Systems is a company that is modernizing reentry capsule production using an automated facility that can make capsules at a much lower cost and much faster.
Terray Therapeutics
Series B in 2024
Founded in 2018, Terray Therapeutics is a biotechnology company based in Pasadena, California. It integrates experimentation and computation to enhance small molecule drug discovery, focusing on intractable diseases. The company's platform generates precise data through a rapid design-make-test-analyze cycle, enabling efficient exploration of chemical space.
Slingshot AI
Seed Round in 2024
Slingshot AI is a research company dedicated to enhancing global access to mental healthcare through artificial intelligence. Based in New York City and London, the company develops advanced large language models to understand human psychology deeply, empowering individuals to cope with daily challenges and seek mental support.
Levels develops a health and wellness platform that monitors metabolic fitness by tracking blood glucose in real time, enabling users to optimize their diet and exercise. The company offers a wellness wearable device paired with a platform that provides real-time feedback on how the body responds to dietary and lifestyle choices, helping users tailor their routines to personal goals. Founded in 2019, Levels operates as a remote-first company focused on helping individuals understand their metabolism to improve health outcomes.
Grayce, Inc. is a health care agency based in San Francisco that specializes in providing personalized guidance and support for families caring for aging adults and children. Founded in 2019, the company offers a range of services designed to assist caregivers with various aspects of care, including insurance, finances, legal plans, medical care, home care, housing, daily needs, and overall well-being. Each member of Grayce receives dedicated support from a social worker who helps manage their comprehensive care needs by planning, prioritizing, identifying resources, coordinating care, and advocating on their behalf. Through its social care management platform, Grayce empowers family caregivers to navigate the complexities of caring for vulnerable loved ones.
Two Chairs
Series C in 2024
Two Chairs is a mental health platform founded in 2017, dedicated to making exceptional mental health care universally accessible. The company's innovative approach involves a thorough, research-backed process that pairs patients with their ideal therapists. This matching is supported by an industry-leading measurement-based care system designed to promote quicker patient improvement. With over 500 licensed therapists across 90 areas of expertise, Two Chairs serves more than 20 million covered lives. The company is recognized as a desirable workplace, receiving accolades such as the 2024 Great Place To Work and being named one of the Best Places To Work by the San Francisco Business Times.
Save Da Sea
Seed Round in 2024
Save Da Sea is a producer of plant-based seafood alternatives focused on providing sustainable options for consumers. The company offers a range of products, including plant-based smoked salmon flavored with dill and capers, as well as a tuna salad made with vegan mayo, lemon, and pepper. These products are crafted from wholesome ingredients designed to convincingly replicate the taste and texture of traditional seafood, allowing consumers to enjoy flavorful seafood options while minimizing their environmental impact.
Overture Life
Series B in 2024
Overture Life, Inc. is a biotechnology company based in New York, established in 2017, that specializes in developing robotic solutions for in vitro fertilization (IVF) applications. The company focuses on automating the IVF process through innovative medical devices and embryo testing methodologies, which enhance the efficiency and success rates of fertility treatments. By optimizing resource use and lowering costs, Overture Life aims to make IVF more accessible to a broader audience. Its technology includes automated cryopreservation and embryo testing services, enabling fertility clinics to identify viable embryos prior to implantation, thereby improving patient outcomes and supporting individuals in their journey to parenthood.
Granata Bio
Series A in 2024
Granata Bio is a biotechnology company established in 2018 that specializes in identifying and developing therapeutics for fertility patients. The company focuses on creating a comprehensive portfolio of fertility-related treatments and leverages its expertise in commercialization, late-stage clinical trials, and regulatory development. Granata Bio aims to address significant challenges faced by medical professionals in fertility treatment. Recently, the company announced a partnership with IBSA Institut Biochimique to co-develop a novel subcutaneous progesterone solution, further enhancing its commitment to improving fertility care.
Alto Neuroscience
Series C in 2023
Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through the integration of patient neurobiology into the drug development process. Utilizing an AI-enabled biomarker platform, the company combines diverse information about patients' brain activity and behavior to create personalized and effective treatment options. Alto Neuroscience is developing several clinical assets, including ALTO-100, ALTO-202, ALTO-101, and ALTO-300, primarily targeting depressive disorders and schizophrenia, identified through independent brain-based biomarkers. By moving away from traditional trial-and-error methods, the company aims to align its innovative therapies with the specific needs of patients, ultimately improving the management of mental health conditions.
Cromatic
Seed Round in 2023
Cromatic develops a software platform that facilitates outsourced R&D for life sciences companies. It streamlines the process of finding and managing scientific outsourcing partners, allowing clients to focus on core scientific work without needing their own lab infrastructure.
Synaptiq
Seed Round in 2023
The Flashcard Platform for Higher Education
InSite Health
Seed Round in 2023
InSite Health offers comprehensive mental health services, including psychiatric evaluations, medication management, psychotherapy, and behavioral threat assessments. They specialize in treating anxiety disorders, PTSD, addiction, depression, ADHD, autism, and behavioral disorders. Their hybrid telepsychiatry model allows for both in-person and remote sessions, ensuring convenient access to care.
Senseye
Venture Round in 2023
Senseye, Inc. is a Los Angeles-based company founded in 2015 that specializes in developing innovative smart contact lenses capable of non-invasively recording and analyzing information from users. These contact lenses are designed to infer human emotions, thoughts, and health states, thereby assisting in various applications such as market research, disease diagnosis, and early detection of medical conditions like strokes and heart attacks. By utilizing novel measurements of ocular physiology, Senseye aims to quantify cognitive abilities and psychological well-being, providing valuable insights into vital signs, attention, cognitive load, and fatigue. The company is committed to advancing technology that enhances emotional responses and mental health diagnostics, enabling clinicians to offer personalized care and effectively track patient outcomes over time.
Alto Pharmacy
Series F in 2023
Founded in 2015, Alto Pharmacy is America's leading digital pharmacy, transforming the $500 billion pharmaceutical industry. It combines expert pharmacist care with purpose-built technology to deliver a more convenient and affordable medication experience for customers. With over three million prescriptions fulfilled and expansion into twelve markets, Alto offers medication management and scheduled delivery through its mobile app, boasting an industry-leading NPS score of 86.
Patient Sortal
Seed Round in 2023
Patient Sortal is a community-based organization focused on supporting individuals reintegrating into society after incarceration by providing essential healthcare services. It employs a blockchain-based data management system to digitize medical records and connect returning citizens with qualified healthcare providers seamlessly. By streamlining the process, Patient Sortal eliminates unnecessary duplicate assessments, appointments, and medication prescription refills, thereby reducing overall healthcare costs per patient. The organization emphasizes evidence-based, data-driven approaches to population health and care management, ensuring that individuals have access to continuous medical care during their transition back into the community. Through these efforts, Patient Sortal addresses critical healthcare challenges faced by this vulnerable population.
Frame - Fertility & Family Building
Seed Round in 2023
Frame develops an evidence-based platform for early detection of risk and care navigation to inform family building and planning. Its approach alleviates a downstream and often costly health crisis for patients, employers, and payers.
Affect Therapeutics
Series A in 2023
Affect Therapeutics offers an integrated digital treatment program for drug and alcohol addiction via a mobile app. The program uses contingency management and other reward systems to encourage healthy behaviors and new habits, aiming to improve member retention and better outcomes.
Luna operates a health and wellness center specializing in physical therapies aimed at addressing various conditions such as orthopedic and sports injuries, senior care, post-surgical rehabilitation, and pain management. The company seeks to enhance the effectiveness of physical therapy by providing greater access to care for patients while offering therapists the autonomy and flexibility necessary to manage their careers effectively. Recognizing the challenges faced by both therapists and patients, Luna is committed to creating an environment that fosters independence and motivation, ultimately leading to improved outcomes and greater satisfaction in the therapy process.
Kindbody
Venture Round in 2023
Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.
Vitalize Care
Pre Seed Round in 2023
Vitalize Care builds software for healthcare organizations to optimize clinical operations, beginning with staffing and scheduling to reduce labor costs and improve efficiency, while easing administrative burdens on clinical leaders. The company also offers a wellness platform designed to support staff mental and emotional well-being, incorporating cognitive behavioral therapy tools and evidence-based digital mental health resources. The solution provides real-time data on staff well-being and performance and includes a dashboard that tracks mental health trends, app engagement, and drivers of burnout. This combination enables employers to understand needs, target interventions, and sustain a healthier, more productive workforce, ultimately supporting better patient care.
2A Biosciences
Seed Round in 2023
Founded in 2022, 2A Biosciences is a pharmaceutical company based in California, USA. It specializes in developing drugs using small molecules that target inflammation through the use of 2A agonists.
Mate Fertility
Series A in 2023
Mate Fertility is a technology-driven fertility clinic founded in 2020 and based in Los Angeles, California. The company aims to make parenthood more accessible by providing comprehensive fertility services at affordable prices. It operates a platform that connects patients to fertility clinics and offers telemedicine options for various treatments and therapies. By delivering end-to-end fertility services, Mate Fertility ensures that patients receive expert guidance and care throughout their fertility journey, making the process more comfortable and manageable.
Sensate
Seed Round in 2023
Sensate is a London‑based company that designs a palm‑sized wearable device and companion app to reduce stress, anxiety, and improve sleep and concentration. The device sits on the chest and delivers sub‑audible tones that stimulate the vagus nerve, providing real‑time relaxation. It is part of BioSelf Technology’s product line and offers a subscription service alongside the hardware.
Carbon Health
Secondary Market in 2023
Carbon Health is a technology-enabled healthcare company that delivers primary and virtual care through a mobile app and a network of clinics. It provides omnichannel services, enabling patients to access care via clinics, pop-up sites, video visits, and a single platform for following treatment plans, managing prescriptions, and viewing lab results. The company has developed COVID-19 tools, including an assessment tool and testing in California. Founded in 2015 and headquartered in San Francisco, Carbon Health aims to provide convenient, accessible care from anywhere.
Mimio Health
Seed Round in 2023
Mimio Health is a nutraceutical company specializing in the research and production of mimetic supplements. Its patent-pending fasting mimetic formulation replicates the body's natural response to fasting by using a rigorously selected combination of bioactive human metabolites, inducing regenerative effects without requiring actual fasting.
Affect Therapeutics
Series A in 2023
Affect Therapeutics offers an integrated digital treatment program for drug and alcohol addiction via a mobile app. The program uses contingency management and other reward systems to encourage healthy behaviors and new habits, aiming to improve member retention and better outcomes.
Galileo is a technology company based in New York, founded in 2014, specializing in healthcare solutions. The company offers a mobile application and online communication platform that enables medical professionals to provide comprehensive clinical care directly from their phones. This includes synchronous and asynchronous telecommunications technologies for connecting providers with patients. Galileo's services cater to diverse patient populations, offering high-touch, data-driven, multi-specialty longitudinal care over the phone, at home, and in various settings. The company is recognized by regional and national health plans, employers, and Fortune 500 companies as a leading solution for improving population health.
Umbra is a space technology company specializing in advanced earth observation systems. It designs, manufactures, and operates satellites to collect high-resolution data, empowering government and commercial clients with consistent, actionable insights for informed decision-making across various applications such as land use monitoring, wildlife protection, and climate change mitigation.
Firefly Health
Venture Round in 2022
Founded in 2016, Firefly Health delivers AI-driven virtual-first primary care. Its platform connects patients with healthcare professionals for convenient, continuous care, focusing on common conditions and women's health issues.
Bionaut Labs
Series B in 2022
Founded in 2016, Bionaut Labs specializes in developing intra-tissue navigation platforms using micro-robots for precise anatomical targeting. Its innovative technology enables remote-controlled delivery of therapeutics to challenging clinical settings, revolutionizing the treatment of central nervous system disorders and other diseases.
Calibrate
Convertible Note in 2022
Calibrate Health, Inc., established in 2020 and based in New York, specializes in digital metabolic health services for sustainable weight loss. The company combines FDA-approved metabolic medications with a comprehensive curriculum and personalized virtual coaching to address the root causes of weight issues and promote long-term behavior change. Calibrate's approach, led by experts in obesity and nutrition science, aims to improve metabolic health and drive lasting results.
Alto Neuroscience
Series B in 2022
Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through the integration of patient neurobiology into the drug development process. Utilizing an AI-enabled biomarker platform, the company combines diverse information about patients' brain activity and behavior to create personalized and effective treatment options. Alto Neuroscience is developing several clinical assets, including ALTO-100, ALTO-202, ALTO-101, and ALTO-300, primarily targeting depressive disorders and schizophrenia, identified through independent brain-based biomarkers. By moving away from traditional trial-and-error methods, the company aims to align its innovative therapies with the specific needs of patients, ultimately improving the management of mental health conditions.
NeuroFlow
Series C in 2022
NeuroFlow, Inc. is a digital health company that develops a cloud-based platform designed to enhance access to behavioral health and engage patients throughout the continuum of mental healthcare. Founded in 2016 and headquartered in Philadelphia, Pennsylvania, NeuroFlow provides healthcare providers with tools for remote patient monitoring and integration of behavioral health across various care settings, including psychology, primary care, and pain management. The platform employs evidence-based practices to track, assess, and engage patients, promoting overall wellness and improving compliance with treatment. By utilizing patient-generated questionnaires and journaling, NeuroFlow enables individuals to monitor their mental health outcomes and achieve tangible progress. The company has established strategic partnerships with organizations like Smart Health Innovation Lab and Mental Health America to further its mission of improving mental health support and outcomes.
Cipher Skin
Venture Round in 2022
Cipher Skin Inc. is a technology company based in Denver, Colorado, founded in 2014. The company specializes in wearable technology that utilizes innovative mesh sensors to conform to the human body, enabling precise measurement and monitoring of vital data. Cipher Skin's platform captures three-dimensional motion data and biosignals, such as heart rate and oxygen saturation, without the need for cameras or bulky equipment. This technology provides actionable insights that can be trusted, allowing physical therapists and trainers to develop safe and effective programs by accurately assessing complex movements, particularly in the upper limbs. Through its advancements, Cipher Skin aims to create the largest and most accurate data DNA platform of the physical world.
Allocations
Venture Round in 2022
Allocations is a technology company based in Miami, Florida, established in 2019. It specializes in fund administration, assisting in the creation of venture capital, real estate, and cryptocurrency funds.
Kindbody
Venture Round in 2022
Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.
Forta provides healthcare services for children, specializing in autism support through applied behavior analysis therapy delivered via online training programs. It operates a telehealth platform offering AI-driven interventions and a personalized care approach that enables parents and caregivers to access structured guidance, expert support, and adaptive treatment plans designed to promote skill building and behavioral improvement.
Motivo Consulting, Inc., operating as Motivo, is an online platform that facilitates connections between mental health therapists and clinical supervisors. Founded in 2017 and based in Atlanta, Georgia, Motivo addresses the need for pre-licensed therapists to complete mandatory supervision hours required for licensure. The platform enables users to engage in secure video conferences, allowing therapists to access a broader range of supervisors, thereby overcoming limitations in available options. Additionally, Motivo offers resources such as peer consultations, webinars, and training, enhancing the professional development of its users. With the growth of telehealth services, Motivo has positioned itself as a leader in therapist telesupervision, ensuring that mental health professionals can find appropriate supervision in a convenient and accessible manner.
Maximus is a consumer telemedicine company for men’s health and hormone optimization. Maximus is revolutionizing the performance enhancement space by democratizing doctor-prescribed protocols developed by some of the world’s leading experts in men’s health. Maximus’ King Protocol utilizes a convenient prescription medication capsule to stimulate natural testosterone production, proven by at-home lab tests.
Maximus was established in 2020 by Cameron Sepah in Santa Monica, California.
Foresight Mental Health
Series C in 2022
Foresight Mental Health is a technology-enabled psychiatry and therapy services company that directly employs psychiatrists, therapists, and psychiatric nurse practitioners to treat patients in its clinics. The company develops technology in collaboration with its providers, leveraging software and biomedical engineering to enhance care. Through a network of clinics, it offers a broad range of mental health treatments and wellness services and maintains patient profiles and a repository of scientific research and clinical information, including genetic profiles, comprehensive symptom profiles, and brain-chemical balance estimates to inform personalized care.
Osmind Inc. is a San Francisco-based public benefit corporation founded in 2020 that specializes in developing healthcare software tailored for mental health providers and their patients. The company focuses on advancing evidence-based medicine to support individuals suffering from moderate to severe mental health conditions. Osmind's electronic health record platform is designed specifically for clinicians and researchers, facilitating interventional treatment workflows. It includes features such as journaling tools and support for health plan reimbursement, empowering healthcare professionals to implement innovative therapeutic approaches and precision psychiatry. By providing robust technology, Osmind aims to inform best practices in patient care and contribute to the development of new life-saving mental health treatments.
Octant Bio
Series B in 2022
Octant Bio is a company focused on developing synthetic technology to enhance health and treat diseases. The firm employs synthetic biology, genome engineering, next-generation sequencing, and computational tools to measure the activity of thousands of receptor pathways in human cells simultaneously. This approach allows scientists to use machine learning methods to engineer small molecules that can interact with multiple receptors, offering new potential for treating complex diseases.
Levels develops a health and wellness platform that monitors metabolic fitness by tracking blood glucose in real time, enabling users to optimize their diet and exercise. The company offers a wellness wearable device paired with a platform that provides real-time feedback on how the body responds to dietary and lifestyle choices, helping users tailor their routines to personal goals. Founded in 2019, Levels operates as a remote-first company focused on helping individuals understand their metabolism to improve health outcomes.
Rejuveron Life Sciences
Angel Round in 2022
Rejuveron Life Sciences AG is a biotechnology company based in Zug, Switzerland, founded in 2019. The company focuses on developing and investing in innovative drugs and technologies aimed at promoting healthy aging and extending lifespan. As a fully integrated platform, Rejuveron combines its investment strategies with a commitment to advancing therapies that address age-related conditions, leveraging both scientific research and entrepreneurial initiatives in the life sciences sector.
PairTree
Seed Round in 2022
PairTree is focused on modernizing the adoption process by leveraging advanced technology to connect prospective adoptive parents with birth mothers. The company has developed a self-matching adoption platform that aims to enhance and expedite opportunities for both adopting families and expectant mothers. This platform is designed to provide a low-cost, fraud-free, and straightforward adoption experience, offering accurate and detailed information to empower parents. By simplifying the adoption process, PairTree seeks to instill confidence and control in families navigating this significant life decision.
Kindbody
Venture Round in 2022
Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.
HealthRhythms
Seed Round in 2022
HealthRhythms develops a digital platform that assesses and monitors mental health conditions using deep machine learning and predictive analytics. Its solution offers real-time behavioral monitoring and personalized interventions, enabling healthcare providers to accurately measure mental health status and deliver timely care.
Alto Pharmacy
Series E in 2022
Founded in 2015, Alto Pharmacy is America's leading digital pharmacy, transforming the $500 billion pharmaceutical industry. It combines expert pharmacist care with purpose-built technology to deliver a more convenient and affordable medication experience for customers. With over three million prescriptions fulfilled and expansion into twelve markets, Alto offers medication management and scheduled delivery through its mobile app, boasting an industry-leading NPS score of 86.
Mightier is a Boston-based company that develops bioresponsive video games and a family program designed to help children regulate emotions. The platform pairs gameplay with a biofeedback heart rate monitor to adjust game difficulty, encouraging kids to stay calm and in control while learning to recognize and manage emotions in daily life. Created through collaboration with Boston Children's Hospital and Harvard Medical School, Mightier aims to address behavioral and emotional challenges by teaching real-time emotion regulation skills. Founded in 2016, the company offers a program that integrates mind-body signals into interactive experiences, enabling children to practice emotional control through engaging, age-appropriate games.
Aptihealth
Series B in 2021
Aptihealth is a technology-driven company specializing in behavioral health engagement. Its innovative platform facilitates seamless integration between physical and behavioral healthcare providers, specialists, prescribers, and patients. The platform employs proprietary screening, assessment, and treatment management protocols to deliver intelligent, virtual integrated care, enhancing patient outcomes.
Bionaut Labs
Series B in 2021
Founded in 2016, Bionaut Labs specializes in developing intra-tissue navigation platforms using micro-robots for precise anatomical targeting. Its innovative technology enables remote-controlled delivery of therapeutics to challenging clinical settings, revolutionizing the treatment of central nervous system disorders and other diseases.
Human API
Venture Round in 2021
Human API is a health data network that facilitates the real-time sharing and viewing of health information across various platforms. Founded in 2013 and headquartered in San Mateo, California, the company connects consumers with their health data from a wide range of sources, including 90% of US hospitals, electronic medical records, pharmacies, labs, and over 300 wearable devices and wellness applications. The platform utilizes a machine learning-powered data pipeline to structure health data into a consistent format, making it accessible for medical researchers and scientists. Importantly, Human API empowers consumers by giving them full control over the sharing of their health information, while also providing companies with a streamlined method to access fragmented health data.
Blackrock Neurotech
Convertible Note in 2021
Blackrock Neurotech develops advanced neurotechnology platforms for recording bio-potentials from the central and peripheral nervous system. Its precision electrode technology enables innovative brain-computer interfaces, facilitating advancements in neural signal processing and stimulation to improve human lives through clinical applications.
Applied Cognition
Venture Round in 2021
Applied Cognition is a clinical-stage therapeutics company focused on advancing the biology of brain glymphatic function for medical care. It develops a digital health management platform with unobtrusive wearable sensors to monitor disease progression and a medical device for translational measurement of brain glymphatic biology, enabling healthcare professionals to diagnose, monitor, and treat Alzheimer's disease.
Grow Therapy
Series A in 2021
Grow Therapy is a mental health technology company focused on enhancing access to quality mental healthcare. It offers therapists and prescribers a comprehensive suite of business tools and services, along with a peer community and a steady stream of matched patient referrals. This support enables practitioners to establish and expand successful in-person and virtual private practices tailored to the needs of their communities. By connecting patients with a diverse range of providers who accept their insurance, Grow Therapy facilitates improved access to mental health services across the United States. The company has built a network of thousands of providers and collaborates with major insurers, ensuring that more individuals receive the care they require.
Jane Technologies
Series C in 2021
Jane Technologies, Inc. is a cannabis retail technology company that operates an online marketplace for cannabis products, enabling consumers to enjoy a confident, safe, and straightforward shopping experience. Founded in 2015 and based in Soquel, California, the company allows users to browse local cannabis products in real-time, comparing them by price, proximity, or popularity. Customers can place orders for pickup at local dispensaries at no charge. Jane Technologies partners with these dispensaries, offering a mutually beneficial arrangement where stores incur costs only for completed orders, making it a cost-effective alternative to other industry software solutions.
MiResource
Seed Round in 2021
MiResource aims to improve global mental health by connecting individuals with appropriate mental healthcare services. Its platform facilitates connections between patients and licensed therapy providers, offering information on various treatment options such as one-on-one talk therapy, medication management, and intensive outpatient programs.
Beckley Psytech
Series B in 2021
Founded in 2014, Beckley Psytech is a UK-based company dedicated to developing psychedelic medicines for treating mental health disorders. It focuses on rigorous scientific research and clinical-stage drug development, aiming to provide innovative treatments for conditions like depression and anxiety.
Paradromics
Seed Round in 2021
Paradromics, Inc. is a company focused on developing advanced brain-machine interfaces aimed at transmitting data between the brain and external devices. Founded in 2015 and based in Austin, Texas, Paradromics manufactures implantable systems that facilitate neural data decoding, converting intricate neural recordings into data streams suitable for various neural prostheses. The company's technology is designed to enhance data transmission rates, providing high-volume, bidirectional data streaming capabilities. This innovation aims to assist individuals with neurodegenerative diseases and other neurological conditions by compensating for the loss of biological connectivity. In addition to its core products, Paradromics also develops applications to support its technology solutions.
Woebot Health
Series B in 2021
Woebot Health is a digital mental healthcare provider that offers a platform designed to deliver personalized support and guidance. Utilizing advanced artificial intelligence and natural language processing, Woebot Health incorporates clinically proven therapeutic techniques into its services. The centerpiece of its offering is Woebot, an engaging relational agent that facilitates continuous, empathic, and user-friendly interactions. This innovative approach allows individuals and organizations to access effective mental health support seamlessly, fitting into daily life and providing help whenever needed. Woebot Health aims to enhance mental well-being through scalable digital tools, making mental health resources more accessible to a broad audience.
TMRW Life Sciences
Series C in 2021
Founded in 2018 by Joshua Abram, Alan Murray, and Dr. Jeffrey Port, TMRW Life Sciences is a pioneering life sciences company specializing in fertility technology. It offers an automated cryo-management platform for eggs and embryos, providing a complete digital chain of custody integrated with robotic storage and monitoring solutions. This innovative approach significantly reduces human error compared to traditional manual methods in IVF procedures.
Psilera
Seed Round in 2021
Psilera is a biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases through the use of psychedelic compounds. The company focuses on creating a new class of neurological medicines, with its lead asset, PSIL-006, being a non-hallucinogenic derivative of psilocybin aimed at treating frontotemporal dementia. Psilera’s approach involves repurposing psychoactive natural products as foundational elements for next-generation therapies that enhance mental health. By prioritizing scientific excellence, Psilera seeks to transform the lives of individuals affected by cognitive, mood, and substance use disorders, marking a significant advancement in the field of mindful medicine.
TRIPP is a digital wellness company that develops immersive experiences for virtual reality, augmented reality, and mobile devices to support emotional well-being. The platform combines mindfulness structures, sound frequencies, visuals, and interactive elements to influence mood—helping users feel calmer, more focused, and less stressed. Aimed at consumer households, TRIPP delivers these experiences through VR, AR, and mobile formats, grounded in research-based content. The company is headquartered in Los Angeles, California, with a satellite development office in Chicago.
Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.
Ksana Health
Seed Round in 2021
Founded in 2019, Ksana Health specializes in digital mental health solutions. Its platform collects user data related to mental health and facilitates its transfer to healthcare practitioners for improved patient care.
Ellipsis Health
Series A in 2021
Founded in 2013, Ellipsis Health is a technology company that uses artificial intelligence to improve behavioral health. It analyzes patient speech and clinical data to predict health outcomes and provide real-time assessments for conditions like depression.
Gilgamesh Pharmaceuticals
Series A in 2021
Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York, focused on developing innovative psychotropic drugs to address mental health issues. Founded in 2019, the company specializes in creating novel compounds that enhance the benefits of traditional psychedelics, improving parameters such as safety, tolerability, duration, and efficacy. Gilgamesh targets a range of neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. With the growing global mental health crisis, the company aims to accelerate the development of new treatments that meet the urgent need for effective solutions in mental health care, leveraging its expertise in medicinal chemistry and drug development.
Alto Neuroscience
Series A in 2021
Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through the integration of patient neurobiology into the drug development process. Utilizing an AI-enabled biomarker platform, the company combines diverse information about patients' brain activity and behavior to create personalized and effective treatment options. Alto Neuroscience is developing several clinical assets, including ALTO-100, ALTO-202, ALTO-101, and ALTO-300, primarily targeting depressive disorders and schizophrenia, identified through independent brain-based biomarkers. By moving away from traditional trial-and-error methods, the company aims to align its innovative therapies with the specific needs of patients, ultimately improving the management of mental health conditions.
LivNao Technologies is a Vancouver-based company that utilizes deep learning technology to monitor and enhance mental health. By passively collecting data, LivNao's platform identifies early indicators of mental health changes before they impact performance and productivity. Once a deviation is detected, the company provides timely interventions tailored to individual health plans, promoting proactive mental health management. LivNao aims to improve the quality of life for individuals and organizations alike, enabling informed decision-making for healthcare systems and insurers. Committed to maintaining privacy and security, LivNao operates in full compliance with HIPAA regulations.
Beckley Psytech
Series B in 2021
Founded in 2014, Beckley Psytech is a UK-based company dedicated to developing psychedelic medicines for treating mental health disorders. It focuses on rigorous scientific research and clinical-stage drug development, aiming to provide innovative treatments for conditions like depression and anxiety.
Peachy Patients
Pre Seed Round in 2021
Peachy Patients is a company that provides a digital payment system aimed at making healthcare more affordable and accessible for patients. The platform allows users to pay their medical bills in one centralized location, ensuring they always receive the correct pricing. In addition to simplifying payments and offering digital invoices, Peachy Patients also enables users to earn cash-back on their expenditures. This holistic approach not only facilitates the management of healthcare costs but also supports patients in improving their credit scores and overall financial health. By placing patients at the forefront of the healthcare experience, Peachy Patients equips them with essential tools and resources for navigating medical expenses effectively.
ATAI Life Sciences
Series D in 2021
ATAI Life Sciences is a biotechnology company focused on developing therapies for mental health disorders, leveraging psychedelic compounds and neuroscience-based approaches. It operates a platform for mental health drug discovery and development and collaborates with partners and research institutions to advance its pipeline, which includes VLS-01, a buccal-film DMT candidate for treatment-resistant depression, and EMP-01, an oral MDMA therapy for social anxiety disorder, along with a drug discovery program aimed at identifying non-hallucinogenic 5-HT2A receptor agonists for depression. The company is based in Munich, Germany, with additional offices in Berlin and London.
NeuroFlow
Series B in 2021
NeuroFlow, Inc. is a digital health company that develops a cloud-based platform designed to enhance access to behavioral health and engage patients throughout the continuum of mental healthcare. Founded in 2016 and headquartered in Philadelphia, Pennsylvania, NeuroFlow provides healthcare providers with tools for remote patient monitoring and integration of behavioral health across various care settings, including psychology, primary care, and pain management. The platform employs evidence-based practices to track, assess, and engage patients, promoting overall wellness and improving compliance with treatment. By utilizing patient-generated questionnaires and journaling, NeuroFlow enables individuals to monitor their mental health outcomes and achieve tangible progress. The company has established strategic partnerships with organizations like Smart Health Innovation Lab and Mental Health America to further its mission of improving mental health support and outcomes.
ATAI Life Sciences
Series C in 2020
ATAI Life Sciences is a biotechnology company focused on developing therapies for mental health disorders, leveraging psychedelic compounds and neuroscience-based approaches. It operates a platform for mental health drug discovery and development and collaborates with partners and research institutions to advance its pipeline, which includes VLS-01, a buccal-film DMT candidate for treatment-resistant depression, and EMP-01, an oral MDMA therapy for social anxiety disorder, along with a drug discovery program aimed at identifying non-hallucinogenic 5-HT2A receptor agonists for depression. The company is based in Munich, Germany, with additional offices in Berlin and London.
Osmind Inc. is a San Francisco-based public benefit corporation founded in 2020 that specializes in developing healthcare software tailored for mental health providers and their patients. The company focuses on advancing evidence-based medicine to support individuals suffering from moderate to severe mental health conditions. Osmind's electronic health record platform is designed specifically for clinicians and researchers, facilitating interventional treatment workflows. It includes features such as journaling tools and support for health plan reimbursement, empowering healthcare professionals to implement innovative therapeutic approaches and precision psychiatry. By providing robust technology, Osmind aims to inform best practices in patient care and contribute to the development of new life-saving mental health treatments.
Gilgamesh Pharmaceuticals
Seed Round in 2020
Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York, focused on developing innovative psychotropic drugs to address mental health issues. Founded in 2019, the company specializes in creating novel compounds that enhance the benefits of traditional psychedelics, improving parameters such as safety, tolerability, duration, and efficacy. Gilgamesh targets a range of neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. With the growing global mental health crisis, the company aims to accelerate the development of new treatments that meet the urgent need for effective solutions in mental health care, leveraging its expertise in medicinal chemistry and drug development.
Field Trip Health
Series B in 2020
Field Trip Health, founded in 2019 and headquartered in Toronto, Canada, offers straightforward, evidence‑based therapies designed to support healing and enhance individuals’ engagement with the world.
Mindstrong
Series C in 2020
Mindstrong Health, established in 2013 and based in Mountain View, California, specializes in remote mental health care. It offers a digital therapeutic platform that combines AI-powered technology, data, and clinical expertise to monitor and improve users' mental health. The platform tracks symptoms continuously through passive data collection from human-computer interactions, enabling evidence-based interventions and personalized support. Services include cognitive behavioral therapy, psychoeducation, crisis management, and more, helping thousands of users, including those with serious mental illness.
Foresight Mental Health
Series A in 2020
Foresight Mental Health is a technology-enabled psychiatry and therapy services company that directly employs psychiatrists, therapists, and psychiatric nurse practitioners to treat patients in its clinics. The company develops technology in collaboration with its providers, leveraging software and biomedical engineering to enhance care. Through a network of clinics, it offers a broad range of mental health treatments and wellness services and maintains patient profiles and a repository of scientific research and clinical information, including genetic profiles, comprehensive symptom profiles, and brain-chemical balance estimates to inform personalized care.
ATAI Life Sciences
Convertible Note in 2020
ATAI Life Sciences is a biotechnology company focused on developing therapies for mental health disorders, leveraging psychedelic compounds and neuroscience-based approaches. It operates a platform for mental health drug discovery and development and collaborates with partners and research institutions to advance its pipeline, which includes VLS-01, a buccal-film DMT candidate for treatment-resistant depression, and EMP-01, an oral MDMA therapy for social anxiety disorder, along with a drug discovery program aimed at identifying non-hallucinogenic 5-HT2A receptor agonists for depression. The company is based in Munich, Germany, with additional offices in Berlin and London.
Foresight Mental Health
Seed Round in 2020
Foresight Mental Health is a technology-enabled psychiatry and therapy services company that directly employs psychiatrists, therapists, and psychiatric nurse practitioners to treat patients in its clinics. The company develops technology in collaboration with its providers, leveraging software and biomedical engineering to enhance care. Through a network of clinics, it offers a broad range of mental health treatments and wellness services and maintains patient profiles and a repository of scientific research and clinical information, including genetic profiles, comprehensive symptom profiles, and brain-chemical balance estimates to inform personalized care.
Pray.com is a social impact company driven by a mission to grow faith & cultivate community. Started by Steve Gatena and his three co-founders in 2016, the company is comprised of people from all backgrounds and is building Pray.com as the digital destination for faith. At Pray.com prayer is the priority and the Pray.com app is the easiest way to incorporate prayer into your daily life. The Pray.com app is the world's #1 app for Daily Prayer and faith-based media content. In 2020, Pray.com became the highest-grossing religious media app in history. In addition to its explosive growth in revenue and subscribers, Pray.com became the first and only mental & spiritual health app federally approved to host the President of the United States as well as other elected officials on the platform so they could promote the power of prayer, highlight the health benefits of faith, and promote religious equity, diversity, and inclusion. As an inter-faith platform, Pray.com has brought together religious, celebrity, and political leaders across industries for major events that pray for, discuss, and act on social issues like: race relations, forced migration, and religious inclusion. Pray.com's marque events include participation from the White House, the National Hispanic Christian Leadership Conference, the Vatican City state, the Southern Baptist Convention, and more. In addition to the success of the Pray.com app, Pray.com's marquee events, and fundraising for social causes, Pray.com's studio division has produced the largest library of Biblically inspired original content in English, Spanish, and Portuguese and its content has been syndicated across broadcast media platforms and new media platforms like SiriusXM Satellite Radio, DirectTV, and YouTube. Pray.com's mission is to grow faith & cultivate community and its vision is to create a world where everyone leaves a legacy of helping others.
Saildrone designs and manufactures wind- and solar-powered autonomous surface vehicles, called Saildrones, to collect ocean data at scale. Founded in 2012 and based in Alameda, California, the company provides high-resolution ocean datasets for climate research, weather forecasting, oceanography, mapping, fish stock analysis, and environmental monitoring. Its vehicles carry sensors and proprietary AI to deliver long-duration, real-time data above and below the sea surface, enabling governments, researchers, and commercial clients to monitor maritime conditions, support border protection and critical infrastructure security, and prevent ecological disasters. Saildrone operates globally, contributing data used to improve planetary models and decision-making across maritime domains.